GlaxoSmithKline plc: PharmaVitae Profile

Publication Date	August 2008
Publisher	Datamonitor
Product Type	Report
Pages	139
ISBN Number	not applicable
Product Code	DAT08408

Price

£3,010.00
approximately: $4,398 | €3,299

PDF

PRINT £3,045 ($4,449 | €3,337)

Order above formats by FAX

Summary

Introduction

This analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark GlaxoSmithKline's performance against key rivals in the ethical pharmaceutical sector
Assess the threat posed by generic competition to GlaxoSmithKline's prescription pharmaceutical business
Analyze the future strategic direction of GSK, namely an enhanced vaccine offering, geographic diversification and increased biologics presence

Content

CHAPTER 1 ABOUT THIS PROFILE
- Executive summary
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
- Data sourcing
- Sales data
- Analyst consensus
CHAPTER 2 EXECUTIVE SUMMARY
- Key findings
- Prescription pharmaceutical sales performance, 200113
- GlaxoSmithKline: PharmaVitae forecasts at a glance
- Strategic insight
- New CEO, new direction?
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
CHAPTER 3 QUARTERLY NEWS UPDATE
- Product developments
- Deals and alliances
- Product deals
- Technology deals
- M&A activity
- Company announcements
- Future product milestones
CHAPTER 4 COMPANY INTRODUCTION
- Key findings
- Background
- M&A history
- Glaxo and Wellcome
- Smith Kline and Beecham
- Key historical drug launches by component GSK companies
- M&A strategy
- R&D overview
- Current corporate structure
CHAPTER 5 COMPANY SALES
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 200113
- Product analysis
- Product analysis, 200107
- Product analysis, 200713
- Therapy area analysis
- Therapy area analysis, 200107
- Therapy area analysis, 200713
- Therapy area focus, 200113
- Geographic analysis
- Geographic analysis, 200107
- Geographic analysis, 200713
- Geographic focus, 200113
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 200713
- Core analysis, 200713
- Core analysis, 200713
- Expiry analysis, 200713
- Launch/core/expiry configuration, 200713
- Molecule type analysis
- Molecule type analysis, 200107
- Molecule type analysis, 200713
- Externalization analysis
- Externalization analysis, 200107
- Externalization analysis, 200713
CHAPTER 6 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Infectious diseases
- Infanrix/Pediarix
- Rotarix
- Synflorix
- Valtrex
- Augmentin
- Respiratory
- Seretide/Advair
- Oncology
- Cervarix
- Tykerb
- CNS
- Seroxat/Paxil
- Lamictal
- Treximet
- Wellbutrin
- Imigran/Imitrex
- Endocrine, metabolic & genitourinary
- Avandia
- Urology & gender specific health
- Avodart
CHAPTER 7 APPENDIX
- Abbreviations
- Exchange rates
TABLE OF TABLES
- Table 1: GlaxoSmithKline PharmaVitae forecasts at a glance
- Table 2: GlaxoSmithKline key product developments, Q1 and Q2 2008
- Table 3: GlaxoSmithKline Product deals and alliances, Q1 and Q2 2008
- Table 4: GlaxoSmithKline Technology deals and alliances, Q1 and Q2 2008
- Table 5: GlaxoSmithKline M&A activity, Q1 2008
- Table 6: GlaxoSmithKline company announcements, Q1 2008
- Table 7: GlaxoSmithKline future product milestones, 200810
- Table 8: GlaxoSmithKline product portfolio overview ($m), 200107
- Table 9: GlaxoSmithKline product portfolio overview ($m), 200713
- Table 10: GlaxoSmithKline product portfolio overview ($m), 200107
- Table 11: GlaxoSmithKline product portfolio overview ($m), 200713
- Table 12: GlaxoSmithKline portfolio overview by geographic region ($m), 200107
- Table 13: GlaxoSmithKline portfolio overview by geographic region ($m), 200713
- Table 14: GlaxoSmithKline launch portfolio overview ($m), 200713
- Table 15: GlaxoSmithKline core portfolio overview ($m), 200713
- Table 16: GlaxoSmithKline expiry portfolio overview ($m), 200713
- Table 17: GlaxoSmithKline portfolio overview by molecule type ($m), 200107
- Table 18: GlaxoSmithKline product portfolio overview by molecule type ($m), 200713
- Table 19: GlaxoSmithKline product portfolio overview by source ($m), 200107
- Table 20: GlaxoSmithKline product portfolio overview by source ($m), 200713
- Table 21: GlaxoSmithKline Key products overview
- Table 22: Infanrix/Pediarix: overview
- Table 23: Infanrix/Pediarix: sales forecast ($m), 200713
- Table 24: Rotarix: overview
- Table 25: Rotarix: sales forecast ($m), 200713
- Table 26: Synflorix: overview
- Table 27: Synflorix: sales forecast ($m), 200713
- Table 28: Valtrex: overview
- Table 29: Valtrex: sales forecast ($m), 200713
- Table 30: Augmentin: overview
- Table 31: Augmentin: sales forecast ($m), 200713
- Table 32: Seretide/Advair: overview
- Table 33: Seretide/Advair: sales forecast ($m), 200713
- Table 34: Cervarix: overview
- Table 35: Cervarix: sales forecast ($m), 200713
- Table 36: Tykerb: overview
- Table 37: Tykerb: sales forecast ($m), 200713
- Table 38: Seroxat/Paxil: overview
- Table 39: Seroxat/Paxil: sales forecast ($m), 200713
- Table 40: Lamictal: overview
- Table 41: Lamictal: sales forecast ($m), 200713
- Table 42: Treximet: overview
- Table 43: Treximet: sales forecast ($m), 200713
- Table 44: Wellbutrin: overview
- Table 45: Wellbutrin: sales forecast ($m), 200713
- Table 46: Imigran/Imitrex: overview
- Table 47: Imigran/Imitrex: sales forecast ($m), 200713
- Table 48: Avandia: overview
- Table 49: Avandia: sales forecast ($m), 200713
- Table 50: Avodart: overview
- Table 51: Avodart: sales forecast ($m), 200713
- Table 52: Exchange rates, 2007
TABLE OF FIGURES
- Figure1: GlaxoSmithKline prescription pharmaceutical performance, sales ($m) and growth rate (%), 200113
- Figure2: GlaxoSmithKline SWOT analysis
- Figure3: M&A/divestment history
- Figure4: GlaxoSmithKline prescription pharmaceutical performance, sales ($m) and growth rate (%), 200113
- Figure5: GlaxoSmithKline key sales growth driver & resistors ($m), 200107
- Figure6: GlaxoSmithKline key sales growth drivers & resistors ($m), 200713
- Figure7: GlaxoSmithKline prescription pharmaceutical sales by therapy area ($m), 200113
- Figure8: GlaxoSmithKline prescription pharma sales by therapy area (% of total), 200113
- Figure9: GlaxoSmithKline prescription pharmaceutical sales by geographic region ($m), 200113
- Figure10: GlaxoSmithKline growth drivers and resistors by geographic region ($m), 200107
- Figure11: GlaxoSmithKline drivers and resistors by geographic region ($m), 200713
- Figure12: GlaxoSmithKline prescription pharmaceutical sales by geographic region (% of total), 200113
- Figure13: GlaxoSmithKline launch/core/expiry configuration ($m), 200713
- Figure14: GlaxoSmithKline prescription pharmaceutical sales by molecule type ($m), 200113
- Figure15: GlaxoSmithKline growth drivers and resistors by molecule type ($m), 200713
- Figure16: GlaxoSmithKline prescription pharmaceutical sales by source ($m), 200113
- Figure17: GlaxoSmithKline growth drivers and resistors by source ($m), 200107
- Figure18: GlaxoSmithKline growth drivers and resistors by source ($m), 200713